Kyverna Therapeutics
KYTX
87 hedge funds and large institutions have $50M invested in Kyverna Therapeutics in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 15 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more call options, than puts
Call options by funds: $3K | Put options by funds: $3K
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
1% less funds holding
Funds holding: 88 → 87 (-1)
7.16% less ownership
Funds ownership: 66.88% → 59.71% (-7.2%)
54% less capital invested
Capital invested by funds: $108M → $50M (-$58.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.46M |
| 2 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$1.17M |
| 3 |
Renaissance Technologies
New York
|
+$237K |
| 4 |
IHG
Insight Holdings Group
New York
|
+$225K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$210K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$6.28M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.73M |
| 3 |
Millennium Management
New York
|
-$1.5M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$1.31M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$712K |
KYTX Hedge Fund Activity: Q1 2025 in Review
87 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q1 2025, worth a combined $50M — down 54% from $108M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of KYTX and 14 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 27 added.
The largest buyer was Citadel Advisors, adding an estimated $2.46M. The largest seller was JP Morgan Chase, cutting an estimated $6.28M.
- 87 institutional investors held Kyverna Therapeutics (KYTX) as of Q1 2025, down from 88 in Q4 2024.
- Funds reported $50M of Kyverna Therapeutics stock for Q1 2025, down 54% quarter-over-quarter.
- 14 funds opened new Kyverna Therapeutics positions in Q1 2025 and 15 closed out, a net change of -1 holder.
- The largest Kyverna Therapeutics buyer in Q1 2025 was Citadel Advisors, an estimated $2.46M added.
- The largest Kyverna Therapeutics seller in Q1 2025 was JP Morgan Chase, an estimated $6.28M sold.
Based on aggregated 13F filings for Q1 2025.